Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 584 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR 2025 ESMO Society Award recipients announced August 5, 2025 ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis... November 11, 2025 FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma August 24, 2020 This Bar of Soap with a Lump Will Help You Remember... May 31, 2019 Load more HOT NEWS FDA Approves Capmatinib for Metastatic NSCLC OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and... ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology... ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer?
